The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

Since the rollout of the conjugate MenC vaccine in 2001 and the MenACWY in 2018, rates of invasive meningococcal disease have ...

GSK gets ready for its next big vaccine launch. GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025.

The U.S. may be headed for a “choose your own adventure” approach to vaccine policy, in which skeptical parents follow the ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60. Health ...

The 17 members of the CDC's vaccine advisory committee, who were ousted last week, argued their abrupt dismissal has "left ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

The Opposition has renewed calls to fund the B strain of the meningococcal vaccine after six out of the seven recorded cases ...

MenACWY (meningococcal conjugate vaccine) protects against the four serogroups A, C, W, and Y. This vaccine is given in two doses: the first dose at age 11 or 12 years, and a booster at age 16 years.

Since the rollout of the conjugate MenC vaccine in 2001 and the MenACWY in 2018, rates of invasive meningococcal disease have dropped dramatically, from 684 cases in 2002, to 136 cases in 2024.